×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
IMVT – immunovant, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
IMVT
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/12
06:13 pm
imvt
Roivant Sciences Ltd. (ROIV) Analyst/Investor Day Transcript [Seeking Alpha]
Neutral
Report
Roivant Sciences Ltd. (ROIV) Analyst/Investor Day Transcript [Seeking Alpha]
12/12
04:30 pm
imvt
Immunovant: 'Buy' On Competitive Batoclimab Landscape And IMVT-1402 Advancement [Seeking Alpha]
Low
Report
Immunovant: 'Buy' On Competitive Batoclimab Landscape And IMVT-1402 Advancement [Seeking Alpha]
12/11
08:06 am
imvt
Roivant Highlights Continued Pipeline Progress and Outlook for Company's Next Phase of Growth at 2025 Investor Day [Yahoo! Finance]
High
Report
Roivant Highlights Continued Pipeline Progress and Outlook for Company's Next Phase of Growth at 2025 Investor Day [Yahoo! Finance]
12/11
01:29 am
imvt
Immunovant Announces Pricing of $550 Million Common Stock Financing
Medium
Report
Immunovant Announces Pricing of $550 Million Common Stock Financing
12/10
01:22 pm
imvt
Immunovant (IMVT) Down 0.6% Since Last Earnings Report: Can It Rebound? [Yahoo! Finance]
Medium
Report
Immunovant (IMVT) Down 0.6% Since Last Earnings Report: Can It Rebound? [Yahoo! Finance]
11/29
01:39 pm
imvt
Oppenheimer Maintains Outperform Rating on Immunovant (IMVT) Following Q2 2026 Earnings [Yahoo! Finance]
Medium
Report
Oppenheimer Maintains Outperform Rating on Immunovant (IMVT) Following Q2 2026 Earnings [Yahoo! Finance]
11/10
04:41 pm
imvt
Immunovant Provides Corporate Updates and Reports Financial Results for the Second Quarter Ended September 30, 2025 [Yahoo! Finance]
Low
Report
Immunovant Provides Corporate Updates and Reports Financial Results for the Second Quarter Ended September 30, 2025 [Yahoo! Finance]
11/10
07:10 am
imvt
Roivant Reports Financial Results for the Second Quarter Ended September 30, 2025, and Provides Business Update [Yahoo! Finance]
Low
Report
Roivant Reports Financial Results for the Second Quarter Ended September 30, 2025, and Provides Business Update [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/12
05:20 pm
imvt
Form SCHEDULE 13D/A Immunovant, Inc. Filed by: Roivant Sciences Ltd.
Low
Report
Form SCHEDULE 13D/A Immunovant, Inc. Filed by: Roivant Sciences Ltd.
12/12
05:17 pm
imvt
Form 4 Immunovant, Inc. For: Dec 12 Filed by: Roivant Sciences Ltd.
Low
Report
Form 4 Immunovant, Inc. For: Dec 12 Filed by: Roivant Sciences Ltd.
12/12
04:15 pm
imvt
Form 8-K Immunovant, Inc. For: Dec 10
Low
Report
Form 8-K Immunovant, Inc. For: Dec 10
12/11
06:40 am
imvt
Form 8-K Immunovant, Inc. For: Dec 10
Medium
Report
Form 8-K Immunovant, Inc. For: Dec 10
12/11
06:02 am
imvt
Form FWP Immunovant, Inc. Filed by: Immunovant, Inc.
High
Report
Form FWP Immunovant, Inc. Filed by: Immunovant, Inc.
12/3
06:15 pm
imvt
Form 4 Immunovant, Inc. For: Dec 01 Filed by: Fromkin Andrew J.
Low
Report
Form 4 Immunovant, Inc. For: Dec 01 Filed by: Fromkin Andrew J.
12/3
06:14 pm
imvt
Form 4 Immunovant, Inc. For: Dec 01 Filed by: Hughes Douglas J.
Low
Report
Form 4 Immunovant, Inc. For: Dec 01 Filed by: Hughes Douglas J.
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/30
Immunovant Announces Positive Clinical Results from Ongoing Phase 2a Proof-of-Concept Study of IMVT-1401, A Novel Investigational Anti-FcRn Antibody Delivered by Subcutaneous Injection, in Thyroid Eye Disease
23.1%
4/14 Immunovant Announces Pricing of $121.2 Million Public Offering 12.8%
12/19 Immunovant Sciences Ltd. Closes Transaction with Health Sciences Acquisitions Corporation 12.1%
1/9 Immunovant (NASDAQ: IMVT) is now covered by analysts at Chardan Capital. They set a "buy" rating on the stock. 6.9%
2/14 Immunovant Reports Financial Results for the Quarter and Nine Months Ending December 31, 2019 6.4%
2/14 Form SC 13G/A Immunovant, Inc. Filed by: Cormorant Asset Management, LP 5.7%
4/8 Form S-1/A Immunovant, Inc. 4.3%
1/10 Immunovant (NASDAQ: IMVT) is now covered by analysts at SunTrust Banks, Inc.. They set a "buy" rating on the stock. 3.8%
3/4 Immunovant (NASDAQ: IMVT) had its "buy" rating re-affirmed by analysts at Nomura. They now have a $27.00 price target on the stock. 3.3%
12/20 Form 4 Health Sciences Acquisit For: Dec 18 Filed by: Health Sciences Holdings, LLC 3.2%
4/14 Immunovant Announces Pricing of $121.2 Million Public Offering 12.8%
12/19 Immunovant Sciences Ltd. Closes Transaction with Health Sciences Acquisitions Corporation 12.1%
1/9 Immunovant (NASDAQ: IMVT) is now covered by analysts at Chardan Capital. They set a "buy" rating on the stock. 6.9%
2/14 Immunovant Reports Financial Results for the Quarter and Nine Months Ending December 31, 2019 6.4%
2/14 Form SC 13G/A Immunovant, Inc. Filed by: Cormorant Asset Management, LP 5.7%
4/8 Form S-1/A Immunovant, Inc. 4.3%
1/10 Immunovant (NASDAQ: IMVT) is now covered by analysts at SunTrust Banks, Inc.. They set a "buy" rating on the stock. 3.8%
3/4 Immunovant (NASDAQ: IMVT) had its "buy" rating re-affirmed by analysts at Nomura. They now have a $27.00 price target on the stock. 3.3%
12/20 Form 4 Health Sciences Acquisit For: Dec 18 Filed by: Health Sciences Holdings, LLC 3.2%
TOP News Decliners
2/12
Form SC 13G/A Immunovant, Inc. Filed by: ADAGE CAPITAL PARTNERS GP, L.L.C.
-7.3%
2/24 Immunovant (NASDAQ: IMVT) is now covered by analysts at Svb Leerink Llc. They set an "outperform" rating and a $24.00 price target on the stock. -6.0%
3/30 Form 8-K Immunovant, Inc. For: Mar 30 -6.0%
1/17 Form S-1 Immunovant, Inc. -5.5%
2/19 Form 3 Immunovant, Inc. For: Feb 18 Filed by: Venker Eric -3.8%
2/21 Immunovant (NASDAQ: IMVT) had its "buy" rating re-affirmed by analysts at Chardan Capital. -2.8%
2/5 Immunovant (NASDAQ: IMVT) is now covered by analysts at Nomura. They set a "buy" rating and a $27.00 price target on the stock. -2.8%
4/16 Immunovant Announces Closing of $139.4 Million Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares -2.1%
2/10 Immunovant to Present at the 9th Annual SVB Leerink Global Healthcare Conference -2.0%
1/7 Immunovant (NASDAQ: IMVT) is now covered by analysts at Robert W. Baird. They set an "outperform" rating on the stock. -1.9%
2/24 Immunovant (NASDAQ: IMVT) is now covered by analysts at Svb Leerink Llc. They set an "outperform" rating and a $24.00 price target on the stock. -6.0%
3/30 Form 8-K Immunovant, Inc. For: Mar 30 -6.0%
1/17 Form S-1 Immunovant, Inc. -5.5%
2/19 Form 3 Immunovant, Inc. For: Feb 18 Filed by: Venker Eric -3.8%
2/21 Immunovant (NASDAQ: IMVT) had its "buy" rating re-affirmed by analysts at Chardan Capital. -2.8%
2/5 Immunovant (NASDAQ: IMVT) is now covered by analysts at Nomura. They set a "buy" rating and a $27.00 price target on the stock. -2.8%
4/16 Immunovant Announces Closing of $139.4 Million Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares -2.1%
2/10 Immunovant to Present at the 9th Annual SVB Leerink Global Healthcare Conference -2.0%
1/7 Immunovant (NASDAQ: IMVT) is now covered by analysts at Robert W. Baird. They set an "outperform" rating on the stock. -1.9%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: